Evergreen Capital Management LLC Sells 25,323 Shares of Pfizer Inc. $PFE

Evergreen Capital Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 509,959 shares of the biopharmaceutical company’s stock after selling 25,323 shares during the quarter. Evergreen Capital Management LLC’s holdings in Pfizer were worth $12,698,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. State Street Corp increased its holdings in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp increased its holdings in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC boosted its position in shares of Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after acquiring an additional 897,786 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Pfizer by 8.6% during the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares in the last quarter. Finally, Amundi boosted its position in shares of Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after acquiring an additional 4,043,413 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.54 on Tuesday. Pfizer Inc. has a fifty-two week low of $21.87 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $156.61 billion, a P/E ratio of 20.25 and a beta of 0.43. The company’s 50 day moving average price is $27.28 and its two-hundred day moving average price is $26.05.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business posted $0.63 earnings per share. The company’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PFE shares. UBS Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.45.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CICC initiated coverage of Pfizer with an Outperform rating and a $33 price target, signaling institutional upside expectations versus current levels. CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating
• Positive Sentiment: The FDA accepted for Priority Review a sBLA for PADCEV + Keytruda as a perioperative treatment for muscle‑invasive bladder cancer — if approved this could become a new standard of care and expand Pfizer’s oncology revenue stream. U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Neutral Sentiment: Pfizer is listed among 22 companies expanding in Hong Kong — a sign of geographic growth intent but unlikely to drive near‑term earnings surprises. Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP
• Neutral Sentiment: Andrew Baum, Pfizer’s Chief Strategy and Innovation Officer, is transitioning to a new role and will eventually leave as part of a strategic simplification — this could mean organizational refocus but also creates short‑term execution uncertainty. Pfizer’s Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
• Negative Sentiment: Royal Bank of Canada reiterated an “underperform” rating and a $25 price target, implying downside vs. recent levels and pressuring sentiment among value/defensive investors. RBC Reaffirms Underperform on Pfizer

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.